RT Journal Article
T1 Real-World Analysis of Nivolumab and Atezolizumab Efficacy in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer.
A1 Alonso-García, Miriam
A1 Sánchez-Gastaldo, Amparo
A1 Muñoz-Fuentes, Miguel A
A1 Molina-Pinelo, Sonia
A1 Boyero, Laura
A1 Benedetti, Johana Cristina
A1 Bernabé-Caro, Reyes
K1 atezolizumab
K1 immune checkpoint inhibitors (ICIs)
K1 immunotherapy
K1 nivolumab
K1 non-small cell lung cancer (NSCLC)
K1 real-world data
AB Nivolumab (anti-PD-1 antibody) and atezolizumab (anti-PD-L1 antibody) have shown superior survival outcomes and improved adverse effects compared to standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients. However, the efficacy of both treatments has not been directly compared in clinical trials. This retrospective, single-centre study was performed from June 2015 to December 2020 and included a cohort of 158 previously treated patients with stage IV or recurrent NSCLC who received PD-1 (nivolumab) (n = 89) or PD-L1 (atezolizumab) (n = 69) inhibitors at the Virgen del Rocío Hospital in Seville. The objective response rate (ORR) was 22.5% in the nivolumab group and 14.5% in the atezolizumab group (p = 0.140). Multivariate analysis did not show significant differences between the two groups for PFS and OS (PFS hazard ratio (HR): 0.80, 95% confidence interval (CI): 0.55−1.17, p = 0.260; OS HR: 0.79, 95% CI: 0.52−1.21, p = 0.281). Adverse events of all grades occurred in 68 patients in the nivolumab group (76.4%) and in 34 patients in the atezolizumab group (49.3%) (p
SN 1424-8247
YR 2022
FD 2022-04-25
LK http://hdl.handle.net/10668/21533
UL http://hdl.handle.net/10668/21533
LA en
DS RISalud
RD Apr 9, 2025